UPDATE 3-U.S. FDA staff questions small ChemGenex study

Mon Feb 8, 2010 7:57pm EST

* FDA cites small study, low response rate

* Agency questions lack of available test for mutation

* ChemGenex: Risks, benefits of Omapro acceptable

* Wednesday panel meeting postponed due to weather (Adds Wednesday panel meeting postponed)

WASHINGTON, Feb 8 (Reuters) - A small study of ChemGenex Pharmaceuticals Ltd's (CXS.AX) experimental...

admin

Mon Feb 8, 2010 7:01pm EST

* Watchdog recommends against Afinitor, Tasigna and Sprycel

* Limited data to back benefits of three pricey drugs - NICE

LONDON, Feb 9 (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG (NOVN.VX) and one from Bristol-Myers Squibb Co (BMY.N) being used within the state-run health service.

The National Institute for Health and Clinical Excellence (NICE) said...

admin

CancerConsultants.com

Researchers from Italy have reported that Sprycel® (dasatinib) may have significant activity for treating patients with castration-resistant prostate cancer (CRPC) with bone metastases. The details of this Phase II study were published in the December 1, 2009 issue of Clinical Cancer Research.[1]

Taxotere is the single most effective agent for the palliative treatment of CRPC. However, most patients ultimately fail to respond. Recently, researchers...

admin

Public release date: 6-Sep-2009

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego

A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that...

admin

Thu Jul 30, 2009 6:34pm EDT

* Report projects more drug-diagnostic alliances

* "Companion diagnostics" trend on rise

By Julie Steenhuysen

CHICAGO, July 30 (Reuters) - Better diagnostic tests and pressure to lower healthcare costs may finally usher in the era of personalized medicine, in which patients get drugs tailored to their genetic makeup, a new report suggests.

Personalized medicine has been a researcher's dream since...

admin